PubMed Health⌕ Search

PubMed · 16262420

Planar polarized light emission from CdSe nanoparticle clusters.

Abstract

This paper describes synthesis and optical properties of planar clusters of CdSe nanocrystals. The clusters emit linearly polarized light in the plane of the cluster. The emission wavelength of the clusters can be adjusted between 568 and 639 nm with the size of the CdSe nanocrystals. Planar CdSe microclusters were synthesized by reaction of trioctylphosphine oxide-coated CdSe/CdS nanocrystals with 3-aminopropylsilyl-modified Ca(2)Nb(3)O(10) nanosheets in THF. The clusters are 3.92 +/- 1.18 mum length/width and 91 +/- 37 nm thickness, and they consist of alternating layers of Ca(2)Nb(3)O(10) to which CdSe nanocrystals are attached with densities of 5300 +/-310 particles per side of a single Ca(2)Nb(3)O(10) sheet. The chemical inertness of the clusters in coordinating solvents suggests covalent interactions between the aminopropyl groups and CdSe nanocrystals. Upon excitation at lambda(exc) = 400 nm, the clusters emit green (568 nm), orange (589 nm), or red (639 nm) light, depending on the size of the CdSe crystals. The light is emitted preferentially in the cluster plane and it is linearly polarized along the cluster edges. Combined fluorescence microscopy and atomic force microscopy reveal that the directional emission efficiency depends linearly on the thickness of the clusters, which varies between 70 and 180 nm. The ability to manipulate the direction and polarization of the photoemission of CdSe nanoparticles via assembly into 2D structures is of interest for applications of these and similar structures in advanced optical materials and devices.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Jin Young Kim, Hiroki Hiramatsu, Frank E Osterloh. 2005-11-09. Planar polarized light emission from CdSe nanoparticle clusters.. https://doi.org/10.1021/ja0541377

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗